Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare… Read More..

Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023. Founded in 1979, SMDM promotes scientific and methodological rigor in health care decision research and its application to health policy and clinical care. Highlighting the… Read More..

LP-310 is an oral formulation of Lipella's lead asset LP-10. PITTSBURGH, Oct. 20, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved… Read More..